OR WAIT null SECS
Feliza Mirasol is the science editor for BioPharm International.
Recent industry guidance aims to anchor rapid COVID-19 vaccine development in good manufacturing practice protocols.
Major bio/pharmaceutical companies and contract service providers leading the charge to bring COVID-19 vaccines to market are familiar with established good manufacturing practices (GMPs). To support manufacturers in the rush to develop a vaccine, FDA, in June 2020, released industry guidance highlighting the development and licensure of COVID-19 vaccines.
eBook: Regulatory Sourcebook, October 2020
When referring to this article, please cite it as F. Mirasol, “GMPs Guide COVID-19 Vaccine Manufacturing," BioPharm International Regulatory Sourcebook eBook (October 2020).